GlassScriptPhysician profile
Jillian E Zimmer
NPI 1548646524
$4,670.38
in general payments reported to CMS, 2019-2025
25 companies · $87.39 in 2025
The $87.39 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $392 · 2020: $195 · 2021: $258 · 2022: $1,128 · 2023: $1,738 · 2024: $872 · 2025: $87.39.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,024 · Long Term Medical Supply Or Device Loan: $673.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,023.78 |
| Long Term Medical Supply Or Device Loan | $673.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $925.31 | 2022-2025 | Durysta, Xen Glaucoma Treatment System, Alphagan P |
| Halozyme INC | $699.35 | 2019-2024 | Hylenex Recombinant |
| Carl Zeiss Meditec USA, INC. | $673.30 | 2023 | Humphrey Field Analyzer (Hfa3) |
| Alcon Vision LLC | $456.39 | 2021-2024 | Hydrus Microstent, Simbrinza, Centurion |
| Sun Pharmaceutical Industries INC. | $438.62 | 2022-2024 | Cequa |
| Aerie Pharmaceuticals, INC. | $310.38 | 2019-2021 | |
| Allergan, INC. | $199.41 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $188.33 | 2019-2022 | |
| Sight Sciences, INC. | $123.13 | 2021-2024 | Omni Surgical System |
| Ocular Therapeutix, INC. | $100.28 | 2020-2024 | Dextenza |
| Horizon Therapeutics Plc | $99.29 | 2023 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $58.68 | 2024 | Xdemvy |
| Mallinckrodt Hospital Products INC. | $50.59 | 2023 | Acthar |
| Biotissue Holdings INC. | $49.65 | 2022 | |
| Bausch & Lomb Americas INC. | $47.05 | 2022-2024 | Vyzulta |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $41.80 | 2023-2024 | Iyuzeh |
| Astellas Pharma US INC | $31.92 | 2024 | Izervay |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $30.52 | 2020-2021 | |
| Shire North American Group INC | $26.81 | 2019 | |
| Eyevance Pharmaceuticals LLC | $26.77 | 2022-2023 | Flarex |
| Kala Pharmaceuticals, INC. | $23.75 | 2021 | |
| Harrow Eye, LLC | $20.54 | 2024 | Vevye |
| Ivantis, INC | $18.19 | 2021 | |
| Amgen INC. | $16.68 | 2024 | Tepezza |
| Oyster Point Pharma, INC. | $13.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jillian Zimmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.